Article
Radiology, Nuclear Medicine & Medical Imaging
Keno K. Bressem, Lisa C. Adams, Fabian Proft, Kay Geert A. Hermann, Torsten Diekhoff, Laura Spiller, Stefan M. Niehues, Marcus R. Makowski, Bernd Hamm, Mikhail Protopopov, Valeria Rios Rodriguez, Hildurn Haibel, Judith Rademacher, Murat Torgutalp, Robert G. Lambert, Xenofon Baraliakos, Walter P. Maksymowych, Janis L. Vahldiek, Denis Poddubnyy
Summary: This study developed a deep neural network to detect changes in the sacroiliac joints indicative of axial spondyloarthritis on MRI. The results showed that the neural network had high accuracy in detecting inflammatory and structural changes.
Review
Rheumatology
Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde
Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Filip E. Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A. van Gaalen, Pal Geher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina Lopez-Medina, Pedro M. Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compan, Michael J. Nissen, Fernando M. Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziade, Desiree van der Heijde
Summary: The ASAS-EULAR recommendations provide updated guidance on the management of axial spondyloarthritis, including treatment targets, non-pharmacological interventions, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the first-line pharmacological treatment. For patients with comorbidities, the use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is recommended. The recommendations also cover the management of extramusculoskeletal manifestations, tapering of bDMARDs, and surgical interventions.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Multidisciplinary Sciences
Kate L. Lapane, Divya Shridharmurthy, Sara Khan, Daniel Lindstrom, Ariel Beccia, Esther Yi, Jonathan Kay, Catherine Dube, Shao-Hsien Liu
Summary: Primary care physicians lack awareness of existing axSpA classification criteria and struggle to differentiate between inflammatory and mechanical back pain. They believe an improved screening tool and strong evidence base are necessary, and integrating the screening tool into workflow, possibly through technology, can enhance efficiency in busy primary care practices.
Article
Multidisciplinary Sciences
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
Summary: HLA-B27 positive patients with axial spondyloarthritis (AxSpA) tend to have lower disease activity compared to HLA-B27 negative patients, as indicated by higher BASDAI scores. HLA-B27 positive patients with mild back pain are more likely to be diagnosed with AxSpA, suggesting a cognitive bias introduced by the HLA-B27 test.
SCIENTIFIC REPORTS
(2021)
Review
Medicine, General & Internal
Fausto Salaffi, Cesare Siragusano, Alessandra Alciati, Giulia Cassone, Salvatore D'Angelo, Serena Guiducci, Ennio Giulio Favalli, Fabrizio Conti, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula, Fabiola Atzeni
Summary: Axial spondyloarthritis (axSpA) is a group of chronic rheumatic diseases primarily affecting the axial skeleton. It includes ankylosing spondylitis, reactive arthritis, arthritis/spondylitis associated with psoriasis (PsA), and arthritis/spondylitis associated with inflammatory bowel diseases (IBD). Pain is a common and important symptom of axSpA, which can progress to chronic pain and significantly impact the quality of life. The development of axSpA inflammation involves complex interactions between genetic, epigenetic, and environmental factors, as well as dysregulated immune responses. Inhibition of IL-23 and IL-17 has been explored as a potential therapeutic strategy for axSpA.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Christopher Ritchlin, Iannis E. Adamopoulos
Summary: Axial spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton associated with significant pain and disability. The discovery of the IL-23/IL-17 pathway led to the development of highly effective antibodies directed toward IL-17A for the treatment of axSpA. New agents with dual inhibition of IL-17A and F isoforms, along with oral small molecule agents targeting the Jak-STAT pathway, have also shown efficacy in treating axSpA.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Rheumatology
Zhixiu Li, Mohammad Kazim Khan, Sjef M. van der Linden, Bjorn Winkens, Peter M. Villiger, Heinz Baumberger, Hermine van Zandwijk, Muhammad Asim Khan, Matthew A. Brown
Summary: This study found that patients with ankylosing spondylitis (AS) have a higher mortality rate compared to the general population, and healthy individuals carrying the HLA-B27 gene also have a similar risk. Additionally, female patients have a lower life expectancy. However, in the overall European population, the presence of the HLA-B27 gene does not affect survival or the risk of death from cardiovascular disease.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Krystel Aouad, Daniel Wendling, Maxime Breban, Sabrina Dadoun, Christophe Hudry, Anna Molto, Edouard Pertuiset, Laure Gossec
Summary: French rheumatologists focused on morning stiffness and axial pain when conceptualizing remission in axSpA, with less emphasis on fatigue. Elements prioritized for remission included morning stiffness, extra-articular manifestations, and NSAID use.
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Immunology
Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu
Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Torsten Diekhoff, Iris Eshed, Felix Radny, Katharina Ziegeler, Fabian Proft, Juliane Greese, Dominik Deppe, Robert Biesen, Kay Geert Hermann, Denis Poddubnyy
Summary: The study found that compared to CT and MRI, X-ray had lower sensitivity and inferior specificity for axSpA. However, CT showed the best inter-rater reliability, highlighting the importance of structural lesions for the differential diagnosis in axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Biochemistry & Molecular Biology
Sergio Del Vescovo, Vincenzo Venerito, Claudia Iannone, Giuseppe Lopalco
Summary: Axial spondyloarthritis (axial-SpA) is a multifactorial disease characterized by inflammation in sacroiliac joints and spine, bone reabsorption, and aberrant bone deposition, which may lead to ankylosis. The disease pathogenesis involves a complex interplay between genetic, immunological, mechanical, and bioenvironmental factors. HLA-B27 plays a significant role as the most important genetic factor, but the disease can also develop in its absence. The innate immune system and T cell adaptive response both contribute to the onset of axial-SpA, leading to the production of proinflammatory molecules and activation of intracellular pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Bartosz Bugaj, Joanna Wielinska, Katarzyna Bogunia-Kubik, Jerzy Swierkot
Summary: This study identified new biomarkers associated with the clinical presentation and treatment response in axSpA patients. SNPs can be used to identify high-risk patients and initiate early treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Nutrition & Dietetics
Pascale Vergne-Salle, Laurence Salle, Anne Catherine Fressinaud-Marie, Adeline Descamps-Deplas, Francois Montestruc, Christine Bonnet, Philippe Bertin
Summary: The diet of axial spondyloarthritis patients can affect disease activity. Low intake of omega-3 PUFAs and fiber, and high intake of ultra-transformed foods are associated with high disease activity in axSpA.
Letter
Rheumatology
Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Bernice L. Sim, Beatrice Z. Sim, Matthew Tunbridge, David F. L. Liew, Philip C. Robinson
Summary: This systematic review identified 30 studies involving 47 patients with myelosuppression caused by colchicine. Most patients had comorbidities, such as renal impairment, and were taking CYP3A4 or P-gp inhibitors. The severity of myelosuppression varied, ranging from moderate anemia to severe thrombocytopenia, neutropenia, and leukopenia.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Christopher McMaster, David F. L. Liew, Susan Lester, Adam Rischin, Rachel J. Black, Vibhasha Chand, Ashley Fletcher, Marissa N. Lassere, Lyn March, Philip C. Robinson, Rachelle Buchbinder, Catherine L. Hill
Summary: This study aimed to determine the COVID-19 vaccine hesitancy rates among inflammatory arthritis patients and identify factors associated with changing vaccine hesitancy over time. The findings showed that beliefs about medication harm and overuse before the pandemic were associated with COVID-19 vaccine hesitancy. Furthermore, individuals who did not seek vaccine information from healthcare professionals were more likely to develop vaccine hesitancy during the pandemic.
Article
Rheumatology
Manuel F. Ugarte-Gil, Graciela S. Alarcon, Andrea M. Seet, Zara Izadi, Anna D. Montgomery, Ali Duarte-Garcia, Emily L. Gilbert, Maria O. Valenzuela-Almada, Leanna Wise, Jeffrey A. Sparks, Tiffany Y. -T. Hsu, Kristin M. D'Silva, Naomi J. Patel, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Lindsay Jacobsohn, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany
Summary: A study on individuals with SLE in the US found that Black and Hispanic patients had higher odds of experiencing more severe COVID-19 outcomes compared to White patients, which may be attributed to socioeconomic and health disparities.
ARTHRITIS CARE & RESEARCH
(2023)
Editorial Material
Rheumatology
Muhammad Asim Khan, Su-Boon Yong, James Cheng-Chung Wei
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Marina Magrey, Jessica A. A. Walsh, Sandra Flierl, Richard A. A. Howard, Renato C. C. Calheiros, David Wei, Muhammad A. A. Khan
Summary: This study investigated the impact of axial spondyloarthritis (axSpA) on work activity, day-to-day function, mental health, relationships, and quality of life among US patients. The results showed that most patients experienced a significant delay in the diagnosis of axSpA, with a longer delay in women compared to men. Patients also reported active disease, psychological distress, and impaired function. The study highlighted the disease burden and limitations in daily activities associated with axSpA.
ACR OPEN RHEUMATOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Victor Yang, Tue W. Kragstrup, Christopher McMaster, Pankti Reid, Namrata Singh, Stine R. Haysen, Philip C. Robinson, David F. L. Liew
Summary: Janus kinase inhibitors (JAKi) have shown great potential as immune-modulating therapies for chronic inflammatory diseases. However, concerns about cardiovascular and cancer risks have arisen from recent studies, particularly in patients with rheumatoid arthritis and existing cardiovascular risk. While this risk has not been fully demonstrated in other patient populations, it has led to a re-evaluation of the use of JAKi in various contexts. Clinicians must carefully consider these risks and other factors when considering JAKi as a treatment option for their patients.
Editorial Material
Rheumatology
Muhammad Asim Khan, Su-Boon Yong, Sjef van Der Linden
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith
Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Muhammad A. Khan
Summary: This article reviews the 50th anniversary of the discovery of the strong association between HLA-B*27 and AS, summarizes the recent findings, and highlights the presence of clonally expanded CD8+ T cells in AS patients who carry the HLA-B*27 gene. The study also reveals the distinct affinity of the T-cell receptors alpha and beta chain motifs for specific peptides, leading to an autoimmune response and the onset of the disease.
CURRENT RHEUMATOLOGY REPORTS
(2023)
Letter
Rheumatology
Zachary S. Wallace, Jeffrey A. Sparks, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany
ANNALS OF THE RHEUMATIC DISEASES
(2023)